Bumetanide

Overview

Bumetanide is a potent loop diuretic used to treat edema associated with heart failure, liver cirrhosis, and renal disease, including the nephrotic syndrome. It works by inhibiting the sodium-potassium-chloride symporter in the thick ascending limb of the loop of Henle, thereby increasing urine production.

API suppliers (10)

Suppliers of Bumetanide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• MEDILUX LABORATORIES PVT LTDIndia1 active DMF GMP on record
• Guilin Pharmaceutical Co., Ltd.China1 active DMF
• OLON SPAItaly1 active DMF GMP on record
• INDUSTRIALE CHIMICA SRLItaly1 active DMF GMP on record
• SOLARA ACTIVE PHARMA SCIENCES LTDIndia1 active DMF GMP on record
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• HAINAN POLY PHARM CO LTD1 active DMF GMP on record
• Unichem Laboratories Ltd.India1 active DMF GMP on record
• Allsino Pharmaceutical Co., Ltd.China1 active DMF
• QUIMICA SINTETICA SASpain GMP on record

EU CEP holders (7)

Companies holding a valid EU Certificate of Suitability (CEP) for Bumetanide, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (48 approved US products), the latest listed US patent on Bumetanide expires 14 May 2045. Generic API sourcing typically opens up once these lapse.

Therapeutic areas